ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Pre-Transplant Pharmacogenetics Identifies CYP3A4 and CYP3A5 Heterogeneity among Caucasian Kidney Transplant Recipients

N. Oliver1, L. Lindberg1, S. LeCorchick1, D. Morris1, S. Anand1, T. Srinivas2

1Intermountain Medical Center, Murray, UT, 2University Hospitals Cleveland Medical Center, Cleveland, OH

Meeting: 2020 American Transplant Congress

Abstract number: D-223

Keywords: Gene polymorphism, Immunosuppression, Kidney transplantation

Session Information

Session Name: Poster Session D: Non-Organ Specific: Pharmacogenomics / Pharmacokinetics

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Tacrolimus has always been dosed based on therapeutic drug monitoring, however pharmacogenomics is becoming increasingly more utilized in the era of precision based medicine and is starting to be incorporated into tacrolimus dosing considerations. Consensus guidelines are available recommending increased tacrolimus dose requirements in patients who have intermediate or extensive CYP3A5 metabolism phenotypes. CYP3A4*22 allele carriers have also been shown to have decreased tacrolimus metabolism. Historically, genetic heterogeneity has been generalized between different ethnic groups, i.e., “African populations have lower frequencies of CYP3A5*3 allele”, or “Asian populations have lower CYP2C19 activity”. With the advent of more widely available genetic assays that report individual genetic makeup, it may no longer be appropriate to generalize genetic differences between ethnic groups and instead we should consider heterogeneity within them. We report the CYP3A4 and CYP3A5 polymorphisms among Caucasian kidney transplant recipients.

*Methods: RxMatch® is a DNA testing assay that provides individual information about CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, and CYP4F2 expression. RxMatch® was obtained by cheek swab in the pre-transplant phase during clinic visits. Adult patients who received a kidney transplant at Intermountain Medical Center between June 2017 and Oct 2019 and had RxMatch® testing were included.

*Results: 60 Caucasian kidney transplant recipients received RxMatch® testing. With regards to CYP3A4 activity, 5 patients (8.3%) were classified as intermediate metabolizers based on polymorphisms containing either *1A|*22 or *1B|*22 alleles, and 55 patients (91.6%) had normal activity containing either *1A|*1A or *1A|*1B alleles. Concerning CYP3A5 activity, 49 patients (81.6%) were classified as poor metabolizers containing either *3A|*3A, *3C|*3C, *3A|*3C, *3B|*3C, or *3A|*3B alleles, and 11 patients (18.3%) were classified as intermediate metabolizers containing either *1D|*3A, *1A|*3C, *1A|*3A, or *1D|*3C alleles. 10 patients in this cohort (16.6%) had biopsy proven acute rejection in the first year post transplant; 1 was an intermediate CYP3A4 metabolizer, 1 was an intermediate CYP3A5 metabolizer, and 8 had normal CYP3A4/poor CYP3A5 activity. Intermediate metabolizers exhibited significantly lower tacrolimus troughs on POD1.

*Conclusions: There is considerable heterogeneity within the Caucasian kidney transplant population at our center concerning CYP3A4 and CYP3A5 activity, including genotypes that significantly affect tacrolimus metabolism and dosing. Our results suggest that therapeutic drug monitoring and individualized initial dosing of tacrolimus are better served by pharmacogenetics stratification rather than by broad generalizations based on self-declared race or ethnicity.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Oliver N, Lindberg L, LeCorchick S, Morris D, Anand S, Srinivas T. Pre-Transplant Pharmacogenetics Identifies CYP3A4 and CYP3A5 Heterogeneity among Caucasian Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/pre-transplant-pharmacogenetics-identifies-cyp3a4-and-cyp3a5-heterogeneity-among-caucasian-kidney-transplant-recipients/. Accessed May 9, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences